What's Happening?
Kelun-Biotech presented the first-in-human study results of its novel B7-H3 antibody-drug conjugate (ADC) SKB500 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study involved 192 patients with advanced solid tumors,
including small cell lung cancer (SCLC) and esophageal squamous cell carcinoma (ESCC). SKB500 demonstrated significant antitumor activity, with an objective response rate (ORR) of 42.7% and a disease control rate (DCR) of 83.9% among patients treated at 12 mg/kg. The study highlighted SKB500's potential as a treatment for multiple solid tumors, particularly SCLC, which has limited treatment options.
Why It's Important?
The promising results of SKB500 are significant as they offer new hope for patients with aggressive cancers like SCLC, which have few effective treatment options. The study's findings suggest that SKB500 could become a valuable addition to the arsenal of cancer therapies, potentially improving outcomes for patients with various solid tumors. The development of SKB500 also underscores the growing importance of ADCs in oncology, as they offer targeted treatment options with potentially fewer side effects compared to traditional chemotherapy. This advancement could lead to more personalized and effective cancer treatments.
What's Next?
Kelun-Biotech plans to continue the clinical development of SKB500, with a Phase II exploratory study already underway in China. This study will evaluate SKB500 in combination with immunotherapy and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The company aims to further validate SKB500's clinical value and expand its use across different cancer types. The ongoing research and potential future approvals could position Kelun-Biotech as a leader in the field of innovative cancer therapies, particularly in the ADC space.
